Novartis Korea, Handok sign Galvus co-promotion deal

Published: 2008-01-31 07:00:00

Updated: 2008-01-31 07:00:00

Novartis Korea and Handok Pharm entered into an agreement on January 28 for the co-promotion of Galvus (vildagliptin) to treat a wide range of patients with type 2 diabetes, a progressive disease estimated to affect more than 27 million people in Korea.

Galvus is a member of a new class of med...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK